* IOA-289 first ATX inhibitor to progress to clinic in oncology

Geneva, Switzerland, July 20, 2021: iOnctura SA, a clinical stage oncology company targeting core
resistance and relapse mechanisms at the tumor-stroma-immune interface, announces the start of clinical development for its second program, a next generation autotaxin inhibitor designated IOA-289…

For over 40 years, the Switzerland based pharmaceutical and biotechnology company Helsinn has been committed to providing cutting edge treatments against cancer and other key diseases. Led by CEO Riccardo Braglia, the company maintains a worldwide presence and focus on innovative and quality products designed to help patients receive quality…

Lugano, Switzerland — Shanghai, China, October 12, 2021 — Helsinn Group (“Helsinn”), a Swiss Biopharmaceutical Group with an innovative R&D pipeline in cancer supportive care and oncology therapeutics, strategically investing in a fully integrated targeted therapy structure to develop, manufacture and commercialize small molecules in precision medicine with higher market…

LUGANO, Switzerland, and PALO ALTO, CA, September 29, 2021 — Helsinn Group and BridgeBio Pharma, Inc. (Nasdaq: BBIO), through its affiliate QED Therapeutics, Inc., today announced that Health Canada has approved TRUSELTIQ™ (infigratinib), a small molecule kinase inhibitor that targets fibroblast growth factor receptor (FGFR), under the Notice of Compliance…

Riccardo Braglia

Swiss-Italian Pharmaceutical Entrepreneur Riccardo Braglia

Get the Medium app

A button that says 'Download on the App Store', and if clicked it will lead you to the iOS App store
A button that says 'Get it on, Google Play', and if clicked it will lead you to the Google Play store